Outlook Therapeutics, Inc. (OTLK) Dividend History

Outlook Therapeutics, Inc. (OTLK) is a biopharmaceutical company focused on developing and commercializing ophthalmic biologics. The company's lead product candidate, ONS-5010, is an anti-VEGF monoclonal antibody designed for the treatment of eye diseases such as wet age-related macular degeneration, diabetic retinopathy, and other retinal vascular diseases. Outlook aims to provide accessible and effective treatments for preserving and improving vision.

111 S. Wood Avenue, Iselin, NJ, 08830
Phone: (609) 619-3990
Website:

Dividend History

Outlook Therapeutics, Inc. currently does not pay dividends

Company News

  • Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

    The retinal and fundus camera market is experiencing growth driven by the evolving landscape of imaging technologies, particularly in diagnosing age-related macular degeneration (AMD). The integration of artificial intelligence (AI) into fundus cameras presents a significant opportunity for market growth, with AI algorithms demonstrating high accuracy in detecting diseases like diabetic retinopathy (DR).

    GlobeNewswire Inc.
    Featured Companies: BLCO BMEA EYEN
  • Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

    Outlook Therapeutics, a biopharmaceutical company, announced the pricing of a $13.0 million public offering of common stock and accompanying warrants. The company plans to use the net proceeds for working capital and general corporate purposes.

    Benzinga
  • Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

    ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET.

    GlobeNewswire Inc.
  • Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

    ISELIN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that the European Commission has granted Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD in the EU. LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU.

    GlobeNewswire Inc.
  • Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

    ISELIN, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and Europe, today announced the submission of its Marketing Authorization Application (MAA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) seeking authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD).

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 00:03:38 UTC